[Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova January 1, 2024 D V Kurkin, E I Morkovin, D A Bakulin et al.
Depression is a major cause of disability globally, but current drugs based on the monoamine theory have limited effectiveness. Exploring alternative mechanisms, such as targeting glutamatergic pathways in the central nervous system through modulation of NMDA and AMPA receptors, shows promising results. This review presents existing drugs with glutamatergic activity and new developments aimed at improving pharmacotherapy for depressive disorders.